Related Experiment Video
Updated: Feb 4, 2026
Genome-wide Analysis using ChIP to Identify Isoform-specific Gene Targets
Published on: July 7, 2010
Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy
Jason Roszik1,2, Kari L Ring3, Khalida M Wani4
1Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Abstract:
Although there has been significant progress in prevention and treatment of cervical cancer, this malignancy is still a leading cause of cancer death for women. Anti-angiogenesis and immunotherapy approaches have been providing survival benefits, however, response rates and durability of response need to be improved. There is a clear need for combination therapies that increase effectiveness of these agents and further improve patient outcome. Previous studies have largely focused on gene expression and molecular pathways in untreated cervix cancer. The goal of this study was to evaluate cancer-specific molecular pathways and their correlation with tumor immune profile in recurrent cervical cancer. Tumor and adjacent normal tissues were used to identify potential combination therapy targets. We found that DNA damage repair pathway genes were significantly overexpressed in the tumor. Based on our results and other recent investigations, we suggest that combination immune checkpoint and PARP inhibitor therapy is a high priority consideration for patients with recurrent, previously treated cervical cancer. We also show that multiple epithelial-mesenchymal transition-related genes, including MAP2K4, ID2, JAK1, FGF2, PIK3R1, AKT3, FGF13, and STAT3 may be potential targets. Interestingly, high-throughput analysis of Cancer Genome Atlas data identified distinct targets, including Fatty acid synthase FASN and Matrix Metallopeptidase 1 MMP1 as novel, promising combination therapy partners.
Insights
This study identifies overexpressed DNA damage repair genes in recurrent cervical cancer, suggesting combination immune checkpoint and PARP inhibitor therapy. Novel targets like FASN and MMP1 also show promise for improving patient outcomes.
Area of Science:
- Oncology
- Cancer Genomics
- Immunotherapy
Background:
- Cervical cancer remains a leading cause of cancer death in women despite advances in treatment.
- Current anti-angiogenesis and immunotherapy offer survival benefits but require improved response rates and durability.
- There is a critical need for novel combination therapies to enhance treatment effectiveness and patient outcomes in recurrent cervical cancer.
Purpose of the Study:
- To investigate cancer-specific molecular pathways in recurrent cervical cancer.
- To correlate these pathways with the tumor immune profile.
- To identify potential combination therapy targets for improved patient outcomes.
Main Methods:
- Analysis of tumor and adjacent normal tissues from patients with recurrent cervical cancer.
- Evaluation of gene expression, focusing on DNA damage repair and epithelial-mesenchymal transition pathways.
- High-throughput analysis of Cancer Genome Atlas (TCGA) data.
Main Results:
- Significant overexpression of DNA damage repair pathway genes was observed in tumors.
- Multiple epithelial-mesenchymal transition-related genes (e.g., MAP2K4, JAK1, STAT3) were identified as potential therapeutic targets.
- TCGA data analysis revealed FASN and MMP1 as novel, promising combination therapy partners.
Conclusions:
- Combination therapy with immune checkpoint inhibitors and PARP inhibitors is a high-priority consideration for recurrent cervical cancer.
- Targeting DNA damage repair pathways and specific EMT-related genes may enhance treatment efficacy.
- FASN and MMP1 represent novel targets for future combination strategies in cervical cancer treatment.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
10:34Using an Automated Cell Counter to Simplify Gene Expression Studies: siRNA Knockdown of IL-4 Dependent Gene Expression in Namalwa Cells
Published on: April 14, 2010
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:35Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
00:59Gene Therapy
01:42What is Gene Expression?
Gene expression is the process in which DNA directs the synthesis of functional products, that is, proteins. Cells can regulate gene expression at various stages. It allows organisms to generate different cell types and enables cells to adapt to internal and external factors.
Genetic Information Flows from DNA to RNA to Protein
A gene is a stretch of DNA that serves as the blueprint for functional RNAs and proteins. Since DNA is made up of nucleotides and proteins consist of amino...
01:36What is Gene Expression?
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...